Abstract CT144: Randomized phase II trial of preoperative fulvestrant with or without enzalutamide for ER+/Her2- breast cancer
Anthony Elias(University of Colorado Cancer Center), Jennifer K. Richer(University of Colorado Anschutz Medical Campus), Tessa McSpadden(University of Colorado Cancer Center), Elena Shagisultanova(University of Colorado Anschutz Medical Campus), Julia Wulfkuhle(University of California, San Francisco), Lyndsey S. Crump(University of Colorado Cancer Center), Peter Kabos(University of Colorado Anschutz Medical Campus), Dexiang Gao(University of Colorado Cancer Center), Jennifer R. Diamond(University of Colorado Anschutz Medical Campus), Alyse Staley(University of Colorado Anschutz Medical Campus), Rosa I. Gallagher(George Mason University), Sharon B. Sams(University of Colorado Denver), Nicole S. Spoelstra(University of Colorado Anschutz Medical Campus), Stephanie Biller(University of Colorado Anschutz Medical Campus), Vida Alami(University of Colorado Cancer Center), Gregory A. Vidal(West Cancer Center), Kathryn L. Zolman(University of Colorado Anschutz Medical Campus), Virginia F. Borges(University of Colorado Anschutz Medical Campus), Emanuel Petricoin(George Mason University), Monica Fornier(Cornell University)
Cited by 0
Related Papers
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
|New England Journal of Medicine|2019|846
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
|JAMA Oncology|2020|707
Differential Gene Regulation by the Two Progesterone Receptor Isoforms in Human Breast Cancer Cells
|Journal of Biological Chemistry|2002|574